Paul R. Rhomberg
YOU?
Author Swipe
View article: In vitro activity of omadacycline against bacterial isolates from bone/joint infections and rare pathogens in the SENTRY antimicrobial surveillance program (2015–2023)
In vitro activity of omadacycline against bacterial isolates from bone/joint infections and rare pathogens in the SENTRY antimicrobial surveillance program (2015–2023) Open
The potent omadacycline activity observed in this study suggests potential clinical utility for treatment of bone/joint infections and rarely encountered Gram-positive infections caused by various staphylococci, streptococci, and enterococ…
View article: Characterization of sulopenem antimicrobial activity using <i>in vitro</i> time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolates
Characterization of sulopenem antimicrobial activity using <i>in vitro</i> time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolates Open
Sulopenem is an oral and intravenous penem antibiotic in clinical development for treatment of urinary tract and intra-abdominal infections caused by multidrug-resistant pathogens. This study evaluated in vitro antimicrobial activity of su…
View article: P-1096. Activity of Ibrexafungerp and Comparator Antifungals Tested against <i>Candida</i> and <i>Aspergillus</i> Isolates Collected from Invasive Infections in a Global Surveillance Program in 2023
P-1096. Activity of Ibrexafungerp and Comparator Antifungals Tested against <i>Candida</i> and <i>Aspergillus</i> Isolates Collected from Invasive Infections in a Global Surveillance Program in 2023 Open
Background Ibrexafungerp (IBX) is a novel triterpenoid antifungal agent that was approved by the U.S. FDA for the treatment of vulvovaginal candidiasis (VVC) in 2021. Further studies are ongoing to assess the efficacy of IBX for the treatm…
View article: P-1095. Activity of Rezafungin against Clinical Isolates of Uncommon Species of <i>Candida spp</i>
P-1095. Activity of Rezafungin against Clinical Isolates of Uncommon Species of <i>Candida spp</i> Open
Background Rezafungin (RZF) is a long-acting echinocandin recently approved by the FDA to treat invasive candidiasis (IC) and candidemia. RZF CLSI breakpoints are available for Candida albicans, C. auris (CARS), C. dubliniensis (CDUB), C. …
View article: P-1168. Activity of Isavuconazole and Comparator Agents against Pediatric Fungal Isolates Collected from 2017–2023 in a Global Surveillance Program
P-1168. Activity of Isavuconazole and Comparator Agents against Pediatric Fungal Isolates Collected from 2017–2023 in a Global Surveillance Program Open
Background Isavuconazole (ISA) is an azole antifungal agent with desirable properties, often making it the treatment of choice for invasive fungal infections. In December 2023, ISA became the sole FDA-approved azole antifungal for the trea…
View article: Anidulafungin is a useful surrogate marker for predicting <i>in vitro</i> susceptibility to rezafungin among five <i>Candida</i> species using CLSI methods and interpretive criteria
Anidulafungin is a useful surrogate marker for predicting <i>in vitro</i> susceptibility to rezafungin among five <i>Candida</i> species using CLSI methods and interpretive criteria Open
This study addresses the use of other echinocandins as surrogate markers to predict the susceptibility of rezafungin against the six most common Candida spp. The Clinical Laboratory Standards Institute (CLSI) reference broth microdilution …
View article: Use of voriconazole to predict susceptibility and resistance to isavuconazole for <i>Aspergillus fumigatus</i> using CLSI methods and interpretive criteria
Use of voriconazole to predict susceptibility and resistance to isavuconazole for <i>Aspergillus fumigatus</i> using CLSI methods and interpretive criteria Open
Aspergillus fumigatus is a common cause of pulmonary and invasive mold infections among immunocompromised hosts. Mortality in immunocompromised hosts with invasive Aspergillus infections (IAI) has been reported to be as high as 80%. Theref…
View article: Evaluation of the Activity of Triazoles Against Non-<i>fumigatus Aspergillus</i> and Cryptic <i>Aspergillus</i> Species Causing Invasive Infections Tested in the SENTRY Program
Evaluation of the Activity of Triazoles Against Non-<i>fumigatus Aspergillus</i> and Cryptic <i>Aspergillus</i> Species Causing Invasive Infections Tested in the SENTRY Program Open
The activity of isavuconazole and other triazoles against non-fumigatus (non-AFM) Aspergillus causing invasive aspergillosis was evaluated. A total of 390 non-AFM isolates were collected (1/patient) in 2017–2021 from 41 hospitals. Isolates…
View article: Liberalization of the Systemic Glucose Management is Associated with a Reduced Frequency of Neuroglucopenia in Subarachnoid Hemorrhage Patients: An Observational Cohort Study
Liberalization of the Systemic Glucose Management is Associated with a Reduced Frequency of Neuroglucopenia in Subarachnoid Hemorrhage Patients: An Observational Cohort Study Open
View article: Recent increase in <i>Candida auris</i> frequency in the SENTRY surveillance program: antifungal activity and genotypic characterization
Recent increase in <i>Candida auris</i> frequency in the SENTRY surveillance program: antifungal activity and genotypic characterization Open
We observed an increase in the frequency of Candida auris among invasive candidiasis isolates in the 2022 SENTRY Antifungal Surveillance Program compared to prior years: ≤0.1% before 2018, 0.4%–0.6% from 2018 to 2021, and 1.6% in 2022. C. …
View article: In Vitro Antimicrobial Activity of Taurolidine against Isolates Associated with Catheter-Related Bloodstream Infections
In Vitro Antimicrobial Activity of Taurolidine against Isolates Associated with Catheter-Related Bloodstream Infections Open
Background: Taurolidine exhibits broad antimicrobial activity and is a component of a recently FDA approved catheter lock solution (DefenCath®, taurolidine 13,500 μg/mL and heparin 1000 Units/mL) indicated for reducing the risk of catheter…
View article: <i>In vitro</i> activity of taurolidine against clinical <i>Candida auris</i> isolates: relevance to catheter-related bloodstream infections
<i>In vitro</i> activity of taurolidine against clinical <i>Candida auris</i> isolates: relevance to catheter-related bloodstream infections Open
Candida auris is an evolving and concerning global threat. Of particular concern are bloodstream infections related to central venous catheters. We evaluated the activity of taurolidine, a broad-spectrum antimicrobial in catheter lock solu…
View article: Trends in the activity of mold-active azole agents against <i>Aspergillus fumigatus</i> clinical isolates with and without <i>cyp51</i> alterations from Europe and North America (2017–2021)
Trends in the activity of mold-active azole agents against <i>Aspergillus fumigatus</i> clinical isolates with and without <i>cyp51</i> alterations from Europe and North America (2017–2021) Open
A few microbiology laboratories perform antifungal susceptibility testing locally for systemically active antifungal agents. The identification of emerging azole-resistant Aspergillus fumigatus is worrisome. As such, there is a critical ro…
View article: Use of Isavuconazole Antifungal Medicine to Treat Mold Infections in Asia and the Western Pacific Region: A Plain Language Summary
Use of Isavuconazole Antifungal Medicine to Treat Mold Infections in Asia and the Western Pacific Region: A Plain Language Summary Open
The purpose of this plain language summary is to help you to understand the findings from recent research. The results of this study may differ from those of other studies. Health professionals should make treatment decisions based on all …
View article: 568. Evaluation of the VITEK 2 XL Antimicrobial Susceptibility Testing for Non-fermenter Gram-Negative Bacilli: The Importance of Continuing to Monitor AST Systems
568. Evaluation of the VITEK 2 XL Antimicrobial Susceptibility Testing for Non-fermenter Gram-Negative Bacilli: The Importance of Continuing to Monitor AST Systems Open
Background Pseudomonas aeruginosa (PSA), Acinetobacter calcoaceticus-baumannii complex (ACB), and Stenotrophomonas maltophilia (SM) are difficult-to-treat pathogens contributing significantly to mortality. Monitoring the accuracy of automa…
View article: 1948. Rise of <i>Candida auris</i> Infections Worldwide and Trends on the Activity of Fosmanogepix and Comparator Agents against <i>C. auris</i> Causing Invasive Infections
1948. Rise of <i>Candida auris</i> Infections Worldwide and Trends on the Activity of Fosmanogepix and Comparator Agents against <i>C. auris</i> Causing Invasive Infections Open
Background Candida auris (CAU) epidemiology is evolving rapidly. Manogepix is the active moiety of the novel prodrug antifungal fosmanogepix (FMGX), and has broad-spectrum activity against yeasts and moulds, including CAU. Fluconazole (FLC…
View article: 2114. Evaluation of Isavuconazole Activity against Non-<i>fumigatus Aspergillus</i> and cryptic <i>Aspergillus</i> species Causing Invasive Infections Worldwide
2114. Evaluation of Isavuconazole Activity against Non-<i>fumigatus Aspergillus</i> and cryptic <i>Aspergillus</i> species Causing Invasive Infections Worldwide Open
Background Isavuconazole (ISC) is considered first-line therapy for the treatment of invasive aspergillosis (IA). There is limited data on antifungal susceptibility testing of clinically relevant non-fumigatus (non-AFM) and cryptic species…
View article: 2113. Evaluation of Isavuconazole Activity against <i>Aspergillus fumigatus</i> Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints
2113. Evaluation of Isavuconazole Activity against <i>Aspergillus fumigatus</i> Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints Open
Background Isavuconazole (ISC) was approved by the US FDA and is considered first-line therapy for the treatment of invasive aspergillosis (IA). Azole resistance in Aspergillus fumigatus (AFM) is a growing concern, mainly caused by mutatio…
View article: 1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)
1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021) Open
Background Fluconazole (FLC) resistance (R) is common in C. glabrata (CGLA). Echinocandins (ECHs) are often used as first-line therapy. R to ECHs has been associated with FKS1 and FKS2 gene alterations. Rezafungin (RZF), a new ECH approved…
View article: 2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program
2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program Open
Background Rezafungin (RZF) is a new echinocandin (ECH) approved by the US FDA to treat candidemia and invasive candidiasis (IC). Fluconazole (FLC) resistance (R) is a raising concern to treat IC, and ECHs are often used as first-line ther…
View article: Plain Language Summary: Did the COVID-19 Pandemic Change the Resistance to Current Antifungal Medicines?
Plain Language Summary: Did the COVID-19 Pandemic Change the Resistance to Current Antifungal Medicines? Open
Knowing which fungal species are resistant to each antifungal can help doctors choose the best treatment. The results from this study may help scientists understand the effect of the COVID-19 pandemic on antifungal resistance.
View article: The Loss of Temporal Muscle Volume is Associated with Poor Outcome in Patients with Subarachnoid Hemorrhage: An Observational Cohort Study
The Loss of Temporal Muscle Volume is Associated with Poor Outcome in Patients with Subarachnoid Hemorrhage: An Observational Cohort Study Open
Background Intensive care unit (ICU) acquired weakness is a major contributor to poor functional outcome of ICU patients. Quantification of temporal muscle volume assessed on routine computed tomography (CT) scans may serve as a biomarker …
View article: In Vitro Activity of Isavuconazole and Other Mould-Active Azoles against Aspergillus fumigatus with and without CYP51 Alterations
In Vitro Activity of Isavuconazole and Other Mould-Active Azoles against Aspergillus fumigatus with and without CYP51 Alterations Open
Azole resistance in Aspergillus fumigatus (AFM) is mainly associated with mutations in CYP51A and its promoter region or its homologue CYP51B. We evaluated the in vitro activity of isavuconazole, itraconazole, posaconazole, and voriconazol…
View article: Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific
Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific Open
Isavuconazole is the only US FDA-approved antifungal for treating invasive mucormycosis. We evaluated isavuconazole activity against a global collection of Mucorales isolates. Fifty-two isolates were collected during 2017–2020 from hospita…
View article: 347. Azole Activity against Filamentous Fungi Causing Invasive Infections in Patients from ICU and Non-ICU Units (2017-2021)
347. Azole Activity against Filamentous Fungi Causing Invasive Infections in Patients from ICU and Non-ICU Units (2017-2021) Open
Background Invasive fungal infection (IFI) is associated with high mortality rates in critically ill patients. Appropriate antifungal treatment is crucial for managing IFI. We evaluated the in vitro activity of isavuconazole (ISC), itracon…
View article: 1731. Rezafungin Activity against <i>Candida</i> spp. and <i>Aspergillus</i> spp. Isolates Causing Invasive Infections Worldwide in 2021
1731. Rezafungin Activity against <i>Candida</i> spp. and <i>Aspergillus</i> spp. Isolates Causing Invasive Infections Worldwide in 2021 Open
Background Rezafungin (RZF) is a once-weekly echinocandin (ECH) with a long half-life and front-loaded drug exposure. RZF is in development to treat candidemia and invasive candidiasis and prevent invasive fungal disease caused by Candida,…
View article: 868. In Vitro Activity of Isavuconazole and Other Mould-Active Triazoles Against Aspergillus fumigatus With and Without cyp51 Alterations
868. In Vitro Activity of Isavuconazole and Other Mould-Active Triazoles Against Aspergillus fumigatus With and Without cyp51 Alterations Open
Background Azole resistance in Aspergillus fumigatus (AFM) is mainly associated with mutations in cyp51A and its promoter region or its homologue cyp51B. We evaluated the in vitro activity of isavuconazole (ISC), itraconazole (ITC), posaco…
View article: Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020)
Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020) Open
We evaluated the in vitro activity of manogepix and comparator agents against 1,435 contemporary fungal isolates collected worldwide from 73 medical centers in North America, Europe, the Asia-Pacific region, and Latin America during 2020. …
View article: Brain Tissue Damage Induced by Multimodal Neuromonitoring In Situ during MRI after Severe Traumatic Brain Injury: Incidence and Clinical Relevance
Brain Tissue Damage Induced by Multimodal Neuromonitoring In Situ during MRI after Severe Traumatic Brain Injury: Incidence and Clinical Relevance Open
Both neuromonitoring and early magnetic resonance imaging (MRI) provide crucial information for treatment management and prognosis in patients with severe traumatic brain injury (sTBI). So far, neuromonitoring in situ impedes the routine i…
View article: Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections
Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections Open
Studies demonstrated the impact of the COVID-19 pandemic in the prevalence and susceptibility profiles of bacterial and fungal organisms. We analyzed 4821 invasive fungal isolates collected during 2018, 2019, and 2020 in 48 hospitals world…